Provided by Tiger Trade Technology Pte. Ltd.

Impel NeuroPharma, Inc.

0.0400
0.0000
Volume:- -
Turnover:- -
Market Cap:- -
PE:-0.01
High:0.0400
Open:0.0400
Low:0.0400
Close:0.0400
52wk High:0.0400
52wk Low:0.0400
Shares:- -
Float Shares:- -
Volume Ratio:0.99
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1280
EPS(LYR):-4.5345
ROE:-2546.09%
ROA:-62.49%
PB:0.00
PE(LYR):-0.01

Loading ...

Company Profile

Company Name:
Impel NeuroPharma, Inc.
Exchange:
PINK
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington. On December 19, 2023, Impel Pharmaceuticals Inc, along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.